You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Fluorescence Intensity-based Scoring of Macromolecule Crystallization Plates

    SBC: iXpressGenes, Inc.            Topic: NIGMS

    DESCRIPTION (provided by applicant): Crystallization, followed by subsequent structure determination, is a major step in understanding the structure- function relationship of macromolecules. Understanding macromolecule structure has become a key part in the development of new pharmaceuticals, and is a major area of NIH research. Crystallization however is also the rate limiting step, despite techn ...

    STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Restoring arm and hand motor function with non-invasive spinal stimulation.

    SBC: Q-Track Corporation            Topic: NIAMS

    DESCRIPTION (provided by applicant): Q-Track seeks to develop a Sports Medicine Assessment Tool (SMAT) to provide comprehensive kinematic and physiological data to trainers, coaching staff, and athletes. In addition to the safety benefit of monitoring thevital condition of players in real time, our goal is to develop a fatigue management system. The purpose of this proposal is to integrate kinema ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Inhibitors of IgH Gene Enhancers for the Treatment of Multiple Myeloma

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): DiscoveryBioMed, Inc. (DBM) has launched an innovative and automation-friendly drug discovery program to screen synthetic organic small molecule collections on differentiated human adipocyte platforms to discover a newclass of therapeutic drugs for type 2 diabetes mellitus (T2DM) and obesity. Differentiated human adipocytes from visceral (central abdominal depo ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. A Cell-based Assay for Botulinum Neurotoxin Detection and Development

    SBC: Q-Track Corporation            Topic: NIEHS

    DESCRIPTION (provided by applicant): The proposed effort aims to dramatically enhance the realism of radiation safety training for Emergency Responders, both First Responders, as well as Skilled Support Personnel. The goal is to develop andevaluate realistic dosimetry simulation or Dosimulation tools. These Realistic, Accurate Dosimulation (RAD) tools will be the centerpiece for ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. A Diarylheptanoid Scaffold to Treat Taopathies

    SBC: CFD RESEARCH CORPORATION            Topic: NIGMS

    DESCRIPTION: Pulmonary drug delivery is increasingly used for both treatment of lung diseases (such as asthma and chronic obstructive pulmonary disease) and in delivering drugs to the systemic circulation. To reach the desired effectiveness and safety oforally/nasally inhaled drugs, appropriate deposition of drugs on targeted region is essential. Due to complex pharmaceutical and physiological fa ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. DBM Anti-Proliferative Lead Small Molecules for Polycystic Kidney Disease

    SBC: DISCOVERYBIOMED, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): An important discovery and validation event occurred recently within human cell-based drug discovery programs at DiscoveryBioMed, Inc. (DBM), yielding a lead class of cytostatic anti-proliferative small molecules thatdisplay nanomolar potency and marked efficacy against hyperproliferative human PKD cells that create and line remodeled PKD cysts within emergent ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. SBIR TOPIC 314: DEVELOPMENT OF A HUMAN TISSUE CULTURE SYSTEM THAT MIMICS THE TUMO

    SBC: Vivo Biosciences Inc            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. DNA Pro-Drug Technology in Localized Wound Healing and Tissue Regeneration

    SBC: International Medicine and Biomedical Research            Topic: NIAMS

    DESCRIPTION (provided by applicant): Advancement in wound management or tissue repair has been limited by the complexities, costs and limited efficacy of purified recombinant growth factors. Further, the combination of these recombinant proteins for moresophisticated approaches is complicated by the need for separate biologics. Optimally, we can move to a single biologic DNA pro-drug that provide ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  9. High Efficiency Anti-scatter Grid System for Fluoroscopy

    SBC: X-RAY IMAGING INNOVATIONS            Topic: NIBIB

    DESCRIPTION (provided by applicant): Antiscatter grids currently employed on fluoroscopic systems are limited in their capability to control scatter. As a result, fluoroscopic radiation levels are higher for the average patient than they would be with a more efficient grid system, and higher still for large patients. Poor image quality often increases the beam-on time required to successfully perf ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
  10. Gaze-guided Localized Image Magnification Peripheral Sight Enabler for Low Vision

    SBC: SMART ENGINEERING            Topic: NEI

    DESCRIPTION (provided by applicant): Central vision field loss (CFL) is caused by inherited and acquired diseases that irreversibly damage the fovea while leaving the peripheral retina relatively intact. CFL results in 1,700,000 legal blindness and lowvision (LV) cases in the US. LV rehabilitation is the means of restoring functional abilities modified by CFL so that the patient's quality ...

    SBIR Phase I 2011 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government